Edited by: Stephan Weidinger
Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood
Version of Record online: 11 NOV 2013
© 2013 The Authors. Allergy published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Special Issue: Atopic dermatitis
Volume 69, Issue 1, pages 104–112, January 2014
How to Cite
Protein biomarkers in vernix with potential to predict the development of atopic eczema in early childhood. Allergy 2014; 69: 104–112., , , , , , , , .
- Issue online: 20 JAN 2014
- Version of Record online: 11 NOV 2013
- Manuscript Accepted: 28 SEP 2013
- Swedish Research Council, the Swedish Strategic Foundation. Grant Number: RBd08-0014
- atopic eczema;
- birth cohort;
Atopic eczema (AE) is a chronic inflammatory skin disease, which has increased in prevalence. Evidence points toward lifestyle as a major risk factor. AE is often the first symptom early in life later followed by food allergy, asthma, and allergic rhinitis. Thus, there is a great need to find early, preferentially noninvasive, biomarkers to identify individuals that are predisposed to AE with the goal to prevent disease development.
To investigate whether the protein abundances in vernix can predict later development of AE.
Vernix collected at birth from 34 newborns within the Assessment of Lifestyle and Allergic Disease During INfancy (ALADDIN) birth cohort was included in the study. At 2 years of age, 18 children had developed AE. Vernix proteins were identified and quantified with liquid chromatography coupled to tandem mass spectrometry.
We identified and quantified 203 proteins in all vernix samples. An orthogonal projections to latent structures-discriminant analysis (OPLS-DA) model was found with R2 = 0.85, Q2 = 0.39, and discrimination power between the AE and healthy group of 73.5%. Polyubiquitin-C and calmodulin-like protein 5 showed strong negative correlation to the AE group, with a correlation coefficient of 0.73 and 0.68, respectively, and a P-value of 8.2 E-7 and 1.8 E-5, respectively. For these two proteins, the OPLS-DA model showed a prediction accuracy of 91.2%.
The protein abundances in vernix, and particularly that of polyubiquitin-C and calmodulin-like protein 5, are promising candidates as biomarkers for the identification of newborns predisposed to develop AE.